Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Feb 9, 2021
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Social security affiliation
- • Signed informed consent
- • Adult patient (over 18 years old)
- • RA according to ACR/EULAR 2010 criteria since less than 6 months
- • DAS28 ≥ 3.2 despite methotrexate therapy and initiating for the first time a bDMARD or a tsDMARD
- • Having an internet access at home and using an email address
- Exclusion Criteria:
- • Other arthritis than RA
- • To participate to a blind-randomized study to assess RA treatment
- • Pregnancy or breastfeeding
- • Patient unable to understand the study, unable to give consent
- • Patient deprived of liberty or patient under guardianship
- • Patient refusing to participate in the study
- • Patients having difficulty using connected objects
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Le Mans, , France
Strasbourg, , France
Montpellier, , France
Reims, , France
Bordeaux, , France
Saint étienne, , France
Clermont Ferrand, , France
Paris, , France
Besançon, , France
Caluire Et Cuire, , France
Grenoble, , France
Orléans, , France
Toulouse, , France
Patients applied
Trial Officials
Hubert MAROTTE, PhD
Principal Investigator
CHU SAINT-ETIENNE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials